OSE Immunotherapeutics SA (OSE.PA)
EUR 7.17
(-1.38%)
EUR 7.17
(-1.38%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 35.5 Million EUR | -4.63% |
| 2022 | 37.23 Million EUR | 20.88% |
| 2021 | 30.8 Million EUR | 86.09% |
| 2020 | 16.55 Million EUR | 79.7% |
| 2019 | 9.21 Million EUR | 140.37% |
| 2018 | 3.83 Million EUR | -10.8% |
| 2017 | 4.29 Million EUR | 258.9% |
| 2016 | 1.19 Million EUR | 486.76% |
| 2015 | 204 Thousand EUR | -77.18% |
| 2014 | 894 Thousand EUR | -22.06% |
| 2013 | 1.14 Million EUR | 38.03% |
| 2012 | 831 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 37.15 Million EUR | 0.0% |
| 2023 FY | 35.5 Million EUR | -4.63% |
| 2023 Q2 | 34.31 Million EUR | 0.0% |
| 2023 Q4 | 35.5 Million EUR | 0.0% |
| 2022 FY | 37.23 Million EUR | 20.88% |
| 2022 Q4 | 37.23 Million EUR | 0.0% |
| 2022 Q2 | 28.09 Million EUR | 0.0% |
| 2021 FY | 30.8 Million EUR | 86.09% |
| 2021 Q4 | 30.8 Million EUR | 0.0% |
| 2021 Q2 | 21.75 Million EUR | 0.0% |
| 2020 Q4 | 16.55 Million EUR | 0.0% |
| 2020 FY | 16.55 Million EUR | 79.7% |
| 2020 Q2 | 16.15 Million EUR | 0.0% |
| 2019 FY | 9.21 Million EUR | 140.37% |
| 2019 Q4 | 9.21 Million EUR | 0.0% |
| 2019 Q2 | 4.49 Million EUR | 0.0% |
| 2018 FY | 3.83 Million EUR | -10.8% |
| 2018 Q4 | 3.83 Million EUR | 0.0% |
| 2018 Q2 | 4.1 Million EUR | 0.0% |
| 2017 FY | 4.29 Million EUR | 258.9% |
| 2017 Q2 | 3.34 Million EUR | 0.0% |
| 2017 Q4 | 4.29 Million EUR | 0.0% |
| 2016 Q2 | 1.37 Million EUR | 0.0% |
| 2016 FY | 1.19 Million EUR | 486.76% |
| 2016 Q4 | 1.19 Million EUR | 0.0% |
| 2015 FY | 204 Thousand EUR | -77.18% |
| 2015 Q2 | 600 Thousand EUR | 0.0% |
| 2015 Q4 | 204 Thousand EUR | 0.0% |
| 2014 FY | 894 Thousand EUR | -22.06% |
| 2014 Q4 | 894 Thousand EUR | 0.0% |
| 2014 Q2 | 1.15 Million EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q3 | 1.14 Million EUR | 0.0% |
| 2013 Q4 | 1.14 Million EUR | 0.0% |
| 2013 FY | 1.14 Million EUR | 38.03% |
| 2012 FY | 831 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -3125.068% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 20.558% |
| Adocia SA | 4.54 Million EUR | -682.115% |
| Aelis Farma SA | 2.04 Million EUR | -1633.789% |
| Biophytis S.A. | 3.11 Million EUR | -1041.369% |
| Advicenne S.A. | 15.89 Million EUR | -123.377% |
| genOway Société anonyme | 5.51 Million EUR | -543.342% |
| IntegraGen SA | 642.28 Thousand EUR | -5428.43% |
| Medesis Pharma S.A. | 1.2 Million EUR | -2859.0% |
| Neovacs S.A. | 650 Thousand EUR | -5362.769% |
| NFL Biosciences SA | 39.2 Thousand EUR | -90474.701% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -715.056% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -1711.329% |
| Sensorion SA | 1.24 Million EUR | -2761.446% |
| Theranexus Société Anonyme | 2.46 Million EUR | -1342.993% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -810.929% |
| TheraVet SA | 1 Million EUR | -3448.674% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -414.162% |
| argenx SE | 15.35 Million EUR | -131.262% |
| BioSenic S.A. | 15.57 Million EUR | -128.01% |
| Celyad Oncology SA | 902 Thousand EUR | -3836.585% |
| DBV Technologies S.A. | 4.52 Million USD | -684.534% |
| Galapagos NV | 4.94 Million EUR | -618.204% |
| Genfit S.A. | 62.25 Million EUR | 42.962% |
| GeNeuro SA | 6.49 Million EUR | -446.925% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -10222.093% |
| Innate Pharma S.A. | 30.6 Million EUR | -16.013% |
| Inventiva S.A. | 25.61 Million EUR | -38.616% |
| MaaT Pharma SA | 5.42 Million EUR | -554.525% |
| MedinCell S.A. | 52.8 Million EUR | 32.75% |
| Nanobiotix S.A. | 41.66 Million EUR | 14.767% |
| Onward Medical N.V. | 16.3 Million EUR | -117.76% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -929.034% |
| Oxurion NV | 117 Thousand EUR | -30248.718% |
| Pharming Group N.V. | 123.65 Million EUR | 71.285% |
| Poxel S.A. | 40.14 Million EUR | 11.546% |
| GenSight Biologics S.A. | 1.04 Million EUR | -3288.168% |
| Transgene SA | 17 Thousand EUR | -208770.588% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 98.766% |
| Valneva SE | 132.76 Million EUR | 73.256% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |